CO2023010612A2 - Vacuna recombinante meningocócica b - Google Patents
Vacuna recombinante meningocócica bInfo
- Publication number
- CO2023010612A2 CO2023010612A2 CONC2023/0010612A CO2023010612A CO2023010612A2 CO 2023010612 A2 CO2023010612 A2 CO 2023010612A2 CO 2023010612 A CO2023010612 A CO 2023010612A CO 2023010612 A2 CO2023010612 A2 CO 2023010612A2
- Authority
- CO
- Colombia
- Prior art keywords
- protein
- fhbp
- antigens
- combination
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 2
- 101710186862 Factor H binding protein Proteins 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 abstract 1
- 101710171321 Neuraminyllactose-binding hemagglutinin Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/36—Neisseria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción se refiere a una composición inmunógena que comprende una combinación de antígenos meningocócicos que comprende al menos una proteína de unión al factor H proteína A (fHBP), al menos una proteína fHBP B, al menos una proteína adhesina A de Neisseria (NadA), y al menos una vesícula de membrana externa extraída con detergente (dOMV). Los antígenos meningocócicos pueden ser de Neisseria meningitidis del serogrupo B. La combinación de antígenos proporcionaba una amplia cobertura de cepas bacterianas. Además, la presente descripción se refiere al uso de la composición inmunógena en métodos para producir una respuesta inmunitaria.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21305211 | 2021-02-19 | ||
US202163172885P | 2021-04-09 | 2021-04-09 | |
PCT/US2022/016894 WO2022178196A1 (en) | 2021-02-19 | 2022-02-18 | Meningococcal b recombinant vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023010612A2 true CO2023010612A2 (es) | 2023-09-08 |
Family
ID=80595537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0010612A CO2023010612A2 (es) | 2021-02-19 | 2023-08-15 | Vacuna recombinante meningocócica b |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220265805A1 (es) |
EP (1) | EP4294432A1 (es) |
JP (1) | JP2024507828A (es) |
KR (1) | KR20230147075A (es) |
AU (1) | AU2022223712A1 (es) |
CA (1) | CA3211240A1 (es) |
CO (1) | CO2023010612A2 (es) |
IL (1) | IL305313A (es) |
MX (1) | MX2023009728A (es) |
TW (1) | TW202245836A (es) |
WO (1) | WO2022178196A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022099003A1 (en) | 2020-11-06 | 2022-05-12 | Sanofi | Lipid nanoparticles for delivering mrna vaccines |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
PT761231E (pt) | 1992-06-25 | 2000-06-30 | Smithkline Beecham Biolog | Composicao de vacina contendo adjuvantes |
EP1175912A1 (en) | 1993-03-23 | 2002-01-30 | SmithKline Beecham Biologics SA | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5494808A (en) | 1994-09-15 | 1996-02-27 | Merck & Co., Inc. | Defined medium OMPC fermentation process |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
DE69838294T2 (de) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
MY125387A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
EP2322210A1 (en) | 1999-04-19 | 2011-05-18 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
CA2383413A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
WO2001021152A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
BR0108711A (pt) | 2000-02-28 | 2004-06-22 | Chiron Spa | Expressão heteróloga de proteìnas de neisseria |
MXPA03006561A (es) | 2001-01-23 | 2004-10-15 | Aventis Pasteur | Vacuna del conjugado proteina-polisacarido meningococico, multivalente. |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
BRPI0909820A2 (pt) | 2008-03-05 | 2015-08-11 | Sanofi Pasteur | Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima |
GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
AU2016273825A1 (en) * | 2009-10-27 | 2017-01-05 | Novartis Ag | Modified meningococcal fHBP polypeptides |
BR112012010531A2 (pt) | 2009-10-27 | 2019-09-24 | Novartis Ag | "polipeptídeos de modificação meningocócica fhbp" |
JP2013521770A (ja) * | 2010-03-10 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
CA2790167C (en) | 2010-03-30 | 2021-02-09 | Children's Hospital & Research Center Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
CA2803239A1 (en) * | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
NZ607224A (en) | 2010-09-10 | 2014-11-28 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
JP6042816B2 (ja) | 2011-09-26 | 2016-12-14 | テルモ株式会社 | 液体注入具 |
NZ628449A (en) | 2012-03-09 | 2016-04-29 | Pfizer | Neisseria meningitidis compositions and methods thereof |
BR112016002150A2 (pt) | 2013-08-02 | 2017-09-12 | Children´S Hospital & Res Center At Oakland | proteínas de ligação de fator h de ocorrência natural (fhbp) e métodos de uso das mesmas |
HUE052293T2 (hu) | 2014-02-28 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Módosított fHbp meningococcus-polipeptidek |
EP3127572B1 (en) | 2014-03-31 | 2021-12-22 | Terumo Kabushiki Kaisha | Prefilled syringe |
BE1022641B1 (fr) | 2014-07-17 | 2016-06-23 | Glaxosmithkline Biologicals Sa | POLYPEPTIDES MENINGOCOCCIQUES fHbp MODIFIES |
BR112017001417B1 (pt) * | 2014-07-23 | 2023-11-07 | Children's Hospital & Research Center At Oakland | Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada |
EP3011990A1 (en) | 2014-10-21 | 2016-04-27 | Sulzer Mixpac AG | Dual-chamber syringe |
DK3506935T3 (en) | 2016-09-02 | 2024-04-02 | Sanofi Pasteur Inc | Neisseria meningitidis-vaccine |
EP3607967A1 (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides |
WO2020165711A1 (en) * | 2019-02-11 | 2020-08-20 | Pfizer Inc. | Neisseria meningitidiscompositions and methods thereof |
-
2022
- 2022-02-18 WO PCT/US2022/016894 patent/WO2022178196A1/en active Application Filing
- 2022-02-18 MX MX2023009728A patent/MX2023009728A/es unknown
- 2022-02-18 JP JP2023550019A patent/JP2024507828A/ja active Pending
- 2022-02-18 IL IL305313A patent/IL305313A/en unknown
- 2022-02-18 EP EP22707000.0A patent/EP4294432A1/en active Pending
- 2022-02-18 TW TW111105942A patent/TW202245836A/zh unknown
- 2022-02-18 CA CA3211240A patent/CA3211240A1/en active Pending
- 2022-02-18 AU AU2022223712A patent/AU2022223712A1/en active Pending
- 2022-02-18 US US17/674,932 patent/US20220265805A1/en active Pending
- 2022-02-18 KR KR1020237027927A patent/KR20230147075A/ko unknown
-
2023
- 2023-08-15 CO CONC2023/0010612A patent/CO2023010612A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022223712A9 (en) | 2024-02-22 |
IL305313A (en) | 2023-10-01 |
JP2024507828A (ja) | 2024-02-21 |
AU2022223712A1 (en) | 2023-10-05 |
EP4294432A1 (en) | 2023-12-27 |
WO2022178196A1 (en) | 2022-08-25 |
KR20230147075A (ko) | 2023-10-20 |
MX2023009728A (es) | 2023-08-30 |
US20220265805A1 (en) | 2022-08-25 |
TW202245836A (zh) | 2022-12-01 |
CA3211240A1 (en) | 2022-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2015002157A1 (es) | Una composición inmunogenica que comprende: un sacárido capsular pneumococico conjugado, incluyendo sacarido depolimerizado de serotipo 18c; y antígeno de proteína de unión a factor h (fhbp) menincocócico, pero sin incluir vesículas de membrana meningocócica; metodo de preparación de la composición | |
CO2023010612A2 (es) | Vacuna recombinante meningocócica b | |
CY1117957T1 (el) | Συμπληρωμενο omv εμβολιο εναντι μηνιγγιοκοκκου | |
ES2519440T3 (es) | Vacunas para la protección de amplio espectro contra enfermedades causadas por Neisseria meningitidis | |
CY1112105T1 (el) | Ανοσογονα βακτηριακα κυστιδια με πρωτεϊνες εξωτερικης μεμβρανης | |
JP2004512269A5 (es) | ||
NZ596870A (en) | Vaccine compositions comprising a saponin adjuvant | |
JP2011500662A5 (es) | ||
ECSP10010723A (es) | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso | |
TW200722101A (en) | Novel composition | |
RU2010138815A (ru) | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP | |
RU2007128332A (ru) | Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis | |
NO20071609L (no) | Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker | |
MX348734B (es) | Vacunacion multiple que incluye meningococcus del serogrupo c. | |
BR112012022676A2 (pt) | composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit | |
RU2015100889A (ru) | Вакцины для менингококка серогруппы х | |
WO2010070453A8 (en) | Meningococcal vaccines including hemoglobin receptor | |
DE60325696D1 (de) | Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs | |
JP2022130637A5 (es) | ||
US20110027316A1 (en) | Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same | |
Precioso et al. | A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems | |
CL2023001142A1 (es) | Composiciones y métodos para la vacunación contra neisseria gonorrhoeae | |
Van Den Dobbelsteen et al. | From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine | |
Kligler et al. | Immunization of animals with formolized tissue cultures of rickettsia from European and Mediterranean typhus | |
WO2021240013A3 (en) | Vaccine formulations |